Boehringer Ingelheim and Inventiva collaborate to develop potential new treatments for idiopathic pulmonary fibrosis
Boehringer Ingelheim and Inventiva, a French biopharmaceutical company specialised in the development of innovative therapies for fibrosis, oncology and orphan diseases, announced today, a new multi-year research and drug discovery collaboration and licensing agreement.
Under the terms of the agreement, the Inventiva and Boehringer Ingelheim research teams will jointly validate a new therapeutic concept with the aim of discovering new medicines for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases. The partnership will combine Inventiva’s deep knowhow and proprietary technologies in the field of transcriptional regulation and fibrosis with Boehringer Ingelheim’s capabilities in drug discovery and clinical development of new therapeutic agents.
The new collaboration is an example of Boehringer Ingelheim’s increasing focus on external innovation and builds on the company’s track record in IPF drug development. Boehringer Ingelheim has successfully developed nintedanib (OFEV® ), a small molecule tyrosine kinase inhibitor, approved and marketed globally for the treatment of IPF in adults and will be responsible for clinical development and commercialization of potential drug candidates from the collaboration.
IPF is a debilitating and fatal lung disease with high mortality, affecting as many as 3 million people worldwide. It is characterized by chronic scaring and remodeling of the lung and progressive decline in lung function. IPF is the most common interstitial lung disease encountered worldwide and poses a major public health threat, as 70% to 80% of patients die within only 5 years from the diagnosis. To date, the cause of IPF is unidentified and despite recent progress treatment options for patients are still limited.
“We are very proud to enter into this collaboration with Boehringer Ingelheim, a company well-reputed for its excellent research and development skills in the field of fibrosis, and particularly Idiopathic Pulmonary Fibrosis,” commented Inventiva’s co-founder and CSO Pierre Broqua. We plan, alongside developing our own pipeline, on pursuing our strategy of establishing collaborative research partnerships with the world’s biggest pharmaceutical companies. This new partnership further testifies to Inventiva’s expertise and contributes to strengthening our position as a leading and innovative actor in the field of fibrosis.”
“We are enthusiastic about this partnership and look forward to collaborating with Inventiva’s team to develop a potential new breakthrough therapy for the treatment of Idiopathic Pulmonary Fibrosis,” concluded Clive R. Wood, Ph.D., Senior Corporate Vice President Discovery Research at Boehringer Ingelheim. “We are impressed by Inventiva’s research and drug discovery competencies and deep knowledge of the field. We firmly believe that joining forces with Inventiva will enable us to foster translation of an aspirational new therapeutic concept into eagerly awaited new therapies for patients.”
Inventiva will receive an upfront payment and is eligible to receive research funding, potential research, development, regulatory and commercial milestone payments of up to €170 million and tiered royalties on net sales of the products resulting from the partnership. Full financial details remain undisclosed.
Please click on the link below for ‘Notes to Editors’ and ‘References’:
Dr. Reinhard Malin
Director Corporate Communications
Tel. +49 (6132) 77-90815
Chief Executive Officer
Tel: +33 (0)3 80 44 75 00
Nicolas Merigeau / Arthur Rouillé
Tel: +33 (0) 1 44 71 94 98 / +33 (0)1 44 71 98 51
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
CA-RESMED22.5.2018 14:57 | pressemeddelelse
ResMed Studies Show Remote Monitoring and Automated Resupply Improve Adherence to PAP Therapy
TX-ASURAGEN22.5.2018 14:02 | pressemeddelelse
Asuragen to Launch the AmplideX® PCR/CE DMPK Kit and Present Growing Genetic Testing Portfolio at 2018 European Society of Human Genetics (ESHG) Conference
OR-FLIR-SYSTEMS-INC22.5.2018 14:02 | pressemeddelelse
FLIR Launches Radar and Thermal Products for Border Patrol and the Dismounted Warfighter
FL-WILSONHCG22.5.2018 14:02 | pressemeddelelse
Phil Brakewell Set to Lead WilsonHCG's Executive Search Efforts Across EMEA; Forbes Ranks WilsonHCG Among Best Executive Recruiting Firms
CELGENE22.5.2018 13:32 | pressemeddelelse
Celgene to Present New and Updated Data across a Range of Blood Diseases at EHA 2018
DISPLAYDATA22.5.2018 13:04 | pressemeddelelse
New Research from Displaydata and Planet Retail RNG Estimates That Global Retailers Spent $104 Billion on Manually Changing Price Labels in 2017
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum